JPHC CE: Treatment-Refractory Dravet Syndrome: Considerations for Novel Medications

1.0 NAPNAP contact hour, 1.0 pharmacology contact hour. This continuing education activity is offered free to NAPNAP Members. For non-members, this continuing education activity rate is $10. Before 2018, there were no U.S. Food and Drug Administration approved medications for managing seizures in Dravet syndrome (DS). Common agents used in the antiepileptic drug regimens of patients with DS included clobazam, valproic acid, topiramate, and levetiracetam, among others; however, these agents alone rarely provide adequate seizure control. Management of seizures in DS changed in recent years with the approval of cannabidiol and stiripentol in 2018 and fenfluramine in 2020. This continuing education article summarizes available efficacy and safety data involving cannabidiol, stiripentol, and fenfluramine and provides a practical review of dosing strategies, pharmacokinetics, and monitoring interventions relevant to their use..J Pediatr Health Care. (2022) 36, 479−488

Important: You must be logged in to use your NAPNAP Member ID# and Password to be recognized as a Member of NAPNAP. If you are a current member of NAPNAP, and you are being asked to purchase this activity, please contact the NAPNAP National Office at (877) 662-7627 to request assistance prior to entering any information.

Participants are forbidden to reproduce, republish, redistribute, or resell this course in any other form. For copyright-related questions, please email your question to: ce@napnap.org

Copyright © 2022 by the National Association of Pediatric Nurse Practitioners. Published by Elsevier Inc. All rights reserved.

This continuing education activity is administered by the National Association of Pediatric Nurse Practitioners (NAPNAP) as an Agency providing continuing education credit. Individuals who complete this program and earn a 70% or higher score on the post test will be awarded 1.0 NAPNAP contact hour of which 1.0 contain pharmacology content. 

Keywords: Dravet syndrome, pediatrics, epilepsy, drug therapy

Target Audience

Pediatric-focused advanced practice registered nurses

Learning Objectives

  • Recognize available medications used to manage treatment- refractory Dravet syndrome.
  • Evaluate the pharmacology of three novel antiepileptic medications and the efficacy and safety data available to support their use.
  • State practical considerations relevant to managing medications used to treat Dravet syndrome or related comorbidities in the outpatient setting.
Course summary
Available credit: 
  • 1.00 Contact hours
Course opens: 
09/01/2022
Course expires: 
10/31/2023
Cost:
$10.00
Rating: 
0

Juan Carlos Lopez, PGY-1 Pharmacy Resident, Department of Pharmacy, Boston Medical Center, Boston, MA

Jasmine R. Pare, PGY-2 Pharmacy Resident, Department of Pharmacy, UCSF Benioff Children's Hospital, San Francisco, CA

Allison B. Blackmer, Adjunct Associate Professor of Pharmacy, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO

Lucas E. Orth, Assistant Professor of Pharmacy, Department of Pharmacy, Children’s Hospital Colorado, Aurora, CO

Conflicts of interest: Alison Blackmer disclosed receipt of consulting fees from Wolters Kluwer, Pediatric and Neonatal Lexi-Drugs and the remaining authors, have no additional financial interests nor potential conflicts of interest to disclose.

Correspondence: Lucas E. Orth, PharmD, 12850 E. Montview Blvd, V20-1208; Mail Stop C238, Aurora, CO 80045.;

e-mail: lucas.orth@cuanschutz.edu.

This continuing education activity is administered by the National Association of Pediatric Nurse Practitioners (NAPNAP) as an Agency providing continuing education credit. Individuals who complete this program and earn a 70% or higher score on the post test will be awarded 1.0 NAPNAP contact hour of which 1.0 contain pharmacology content. 

Available Credit

  • 1.00 Contact hours

Price

Cost:
$10.00
Please login or register to take this course.